207 related articles for article (PubMed ID: 33776447)
1. Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy.
Furubayashi N; Negishi T; Sakamoto N; Shimokawa H; Morokuma F; Song Y; Hori Y; Tomoda T; Tokuda N; Seki N; Kuroiwa K; Nakamura M
Onco Targets Ther; 2021; 14():1981-1988. PubMed ID: 33776447
[TBL] [Abstract][Full Text] [Related]
2. Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma.
Furubayashi N; Negishi T; Miura A; Nakamura N; Nakamura M
Res Rep Urol; 2020; 12():455-461. PubMed ID: 33117745
[TBL] [Abstract][Full Text] [Related]
3. Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
Furubayashi N; Minato A; Tomoda T; Hori Y; Kiyoshima K; Negishi T; Haraguchi Y; Koga T; Kuroiwa K; Fujimoto N; Nakamura M
Anticancer Res; 2023 Dec; 43(12):5689-5698. PubMed ID: 38030199
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Furubayashi N; Negishi T; Sakamoto N; Tamura S; Morokuma F; Song Y; Hori Y; Tomoda T; Seki N; Kuroiwa K; Nakamura M
In Vivo; 2021; 35(5):2869-2874. PubMed ID: 34410980
[TBL] [Abstract][Full Text] [Related]
5. Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice.
Furubayashi N; Kuroiwa K; Tokuda N; Tomoda T; Morokuma F; Hori Y; Negishi T; Inoue T; Kumagai M; Nakamura M
J Clin Med Res; 2020 May; 12(5):300-306. PubMed ID: 32489505
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Fradet Y; Bellmunt J; Vaughn DJ; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Nam K; Frenkl TL; Perini RF; de Wit R; Bajorin DF
Ann Oncol; 2019 Jun; 30(6):970-976. PubMed ID: 31050707
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
Giannatempo P; Raggi D; Marandino L; Bandini M; Farè E; Calareso G; Colecchia M; Gallina A; Ross JS; Alessi A; Briganti A; Montorsi F; Madison R; Necchi A
Ann Oncol; 2020 Dec; 31(12):1764-1772. PubMed ID: 32979512
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
[TBL] [Abstract][Full Text] [Related]
9. Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Shimizu T; Miyake M; Nishimura N; Inoue K; Fujii K; Iemura Y; Ichikawa K; Omori C; Tomizawa M; Maesaka F; Oda Y; Miyamoto T; Sakamoto K; Kiba K; Tanaka M; Oyama N; Okajima E; Fujimoto K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406508
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.
Yamamoto Y; Yatsuda J; Shimokawa M; Fuji N; Aoki A; Sakano S; Yamamoto M; Suga A; Tei Y; Yoshihiro S; Kitahara S; Nagao K; Takai K; Kamiryo Y; Akao J; Yamaguchi S; Oba K; Shimabukuro T; Matsumoto H; Kamba T; Matsuyama H
Int J Clin Oncol; 2021 Jan; 26(1):169-177. PubMed ID: 32948925
[TBL] [Abstract][Full Text] [Related]
11. Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
Furubayashi N; Morokuma F; Tomoda T; Hori Y; Negishi T; Miura A; Komori H; Kuroiwa K; Nakamura M
Anticancer Res; 2022 Mar; 42(3):1571-1577. PubMed ID: 35220254
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma.
Furubayashi N; Hori Y; Morokuma F; Tomoda T; Negishi T; Inoue T; Kumagai M; Kuroiwa K; Tokuda N; Nakamura M
Mol Clin Oncol; 2021 May; 14(5):91. PubMed ID: 33767860
[TBL] [Abstract][Full Text] [Related]
14. Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab.
Umeda K; Tanaka N; Yasumizu Y; Takeda T; Matsumoto K; Morita S; Kosaka T; Mizuno R; Oya M
Clin Genitourin Cancer; 2023 Feb; 21(1):128-135. PubMed ID: 36058808
[TBL] [Abstract][Full Text] [Related]
15. Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST.
Kadono Y; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kamijima T; Seto C; Takano A; Yotsuyanagi S; Nakagawa R; Miyagi T; Aoyama S; Asahi H; Fukuda R; Mizokami A
Urol J; 2021 Dec; 19(3):202-208. PubMed ID: 34927229
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
19. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
[TBL] [Abstract][Full Text] [Related]
20. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
Powell SF; Rodríguez-Abreu D; Langer CJ; Tafreshi A; Paz-Ares L; Kopp HG; Rodríguez-Cid J; Kowalski DM; Cheng Y; Kurata T; Awad MM; Lin J; Zhao B; Pietanza MC; Piperdi B; Garassino MC
J Thorac Oncol; 2021 Nov; 16(11):1883-1892. PubMed ID: 34265431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
